Publications by authors named "G Michael Lewitt"

Introduction: Patients with psoriasis report pruritus as their most bothersome symptom. Tapinarof cream 1% once daily demonstrated significant efficacy versus vehicle and was well tolerated in adults with mild to severe plaque psoriasis in two 12-week trials: PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980). Here, we present patient-reported pruritus outcomes from these trials.

View Article and Find Full Text PDF
Article Synopsis
  • Tapinarof cream 1% is a non-steroidal topical treatment confirmed by the FDA for plaque psoriasis in adults and currently being explored for children and atopic dermatitis.
  • The PSOARING phase 3 trials show that tapinarof cream improves psoriasis symptoms significantly with a high number of patients (40.9%) achieving complete clearance of the disease.
  • The treatment is generally well tolerated, with mild side effects like folliculitis and contact dermatitis, and patients reported favorable quality of life improvements.
View Article and Find Full Text PDF

The goal of this study was to investigate the molecular mechanisms responsible for the formation of skin erosions in patients affected by Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC). This ectodermal dysplasia is caused by mutations in the TP63 gene, which encodes several transcription factors that control epidermal development and homeostasis. We generated induced pluripotent stem cells (iPSC) from AEC patients and corrected the TP63 mutations using genome editing tools.

View Article and Find Full Text PDF

The goal of this study was to investigate the molecular mechanisms responsible for the formation of skin erosions in patients affected by Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome (AEC). This ectodermal dysplasia is caused by mutations in the TP63 gene, which encodes several transcription factors that control epidermal development and homeostasis. We generated induced pluripotent stem cells (iPSC) from AEC patients and corrected the TP63 mutations using genome editing tools.

View Article and Find Full Text PDF